CSL Limited (CSLLY)
(Delayed Data from OTC)
$89.60 USD
-0.56 (-0.62%)
Updated Apr 26, 2024 03:56 PM ET
4-Sell of 5 4
F Value B Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CSLLY 89.60 -0.56(-0.62%)
Will CSLLY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CSLLY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CSLLY
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
New Strong Sell Stocks for August 14th
CSLLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Diverse Medical Stocks to Buy for 2023 and Beyond
What Makes CSL Limited Sponsored ADR (CSLLY) a Good Fit for 'Trend Investing'
Other News for CSLLY
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Travere, CSL win conditional nod for kidney disease therapy in EU
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL"